An Online Survey of Hypothyroid Patients Demonstrates Prominent Dissatisfaction
- PMID: 29620972
- PMCID: PMC6916129
- DOI: 10.1089/thy.2017.0681
An Online Survey of Hypothyroid Patients Demonstrates Prominent Dissatisfaction
Abstract
Background: Approximately 15% more patients taking levothyroxine (LT4) report impaired quality of life compared to controls. This could be explained by additional diagnoses independently affecting quality of life and complicating assignment of causation. This study sought to investigate the underpinnings of reduced quality of life in hypothyroid patients and to provide data for discussion at a symposium addressing hypothyroidism.
Methods: An online survey for hypothyroid patients was posted on the American Thyroid Association Web site and forwarded to multiple groups. Respondents were asked to rank satisfaction with their treatment for hypothyroidism and their treating physician. They also ranked their perception regarding physician knowledge about hypothyroidism treatments, need for new treatments, and life impact of hypothyroidism on a scale of 1-10. Respondents reported the therapy they were taking, categorized as LT4, LT4 and liothyronine (LT4 + LT3), or desiccated thyroid extract (DTE). They also reported sex, age, cause of hypothyroidism, duration of treatment, additional diagnoses, and prevalence of symptoms.
Results: A total of 12,146 individuals completed the survey. The overall degree of satisfaction was 5 (interquartile range [IQR] = 3-8). Among respondents without self-reported depression, stressors, or medical conditions (n = 3670), individuals taking DTE reported a higher median treatment satisfaction of 7 (IQR = 5-9) compared to other treatments. At the same time, the LT4 treatment group exhibited the lowest satisfaction of 5 (IQR = 3-7), and for the LT4 + LT3 treatment group, satisfaction was 6 (IQR = 3-8). Respondents taking DTE were also less likely to report problems with weight management, fatigue/energy levels, mood, and memory compared to those taking LT4 or LT4 + LT3.
Conclusions: A subset of patients with hypothyroidism are not satisfied with their current therapy or their physicians. Higher satisfaction with both treatment and physicians is reported by those patients on DTE. While the study design does not provide a mechanistic explanation for this observation, future studies should investigate whether preference for DTE is related to triiodothyronine levels or other unidentified causes.
Keywords: T3; TSH; combination therapy; desiccated thyroid extract; hypothyroidism; levothyroxine.
Conflict of interest statement
A.C.B. is a consultant for Senthier; J.V.H consulted for AbbVie and Allergan. All other authors have nothing to disclose.
Figures
Similar articles
-
Comparative Effectiveness of Levothyroxine, Desiccated Thyroid Extract, and Levothyroxine+Liothyronine in Hypothyroidism.J Clin Endocrinol Metab. 2021 Oct 21;106(11):e4400-e4413. doi: 10.1210/clinem/dgab478. J Clin Endocrinol Metab. 2021. PMID: 34185829 Free PMC article. Clinical Trial.
-
Effects of Long-Term Combination LT4 and LT3 Therapy for Improving Hypothyroidism and Overall Quality of Life.South Med J. 2018 Jun;111(6):363-369. doi: 10.14423/SMJ.0000000000000823. South Med J. 2018. PMID: 29863229 Free PMC article.
-
Liothyronine and Desiccated Thyroid Extract in the Treatment of Hypothyroidism.Thyroid. 2020 Oct;30(10):1399-1413. doi: 10.1089/thy.2020.0153. Epub 2020 May 12. Thyroid. 2020. PMID: 32279609 Free PMC article. Review.
-
Use of thyroid hormones in hypothyroid and euthyroid patients: a THESIS* questionnaire survey of Polish physicians. *THESIS: Treatment of hypothyroidism in Europe by specialists: an international survey.Endokrynol Pol. 2021;72(4):357-365. doi: 10.5603/EP.a2021.0048. Epub 2021 May 19. Endokrynol Pol. 2021. PMID: 34010443
-
Levothyroxine Monotherapy: What Works Better for the Individual With Hypothyroidism?Endocr Pract. 2023 Jul;29(7):572-580. doi: 10.1016/j.eprac.2022.12.013. Endocr Pract. 2023. PMID: 37419564 Review.
Cited by
-
Evaluating health outcomes in the treatment of hypothyroidism.Front Endocrinol (Lausanne). 2022 Oct 18;13:1026262. doi: 10.3389/fendo.2022.1026262. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36329885 Free PMC article. Review.
-
Medically not yet explained symptoms in hypothyroidism.Nat Rev Endocrinol. 2024 Nov;20(11):685-693. doi: 10.1038/s41574-024-01022-7. Epub 2024 Aug 13. Nat Rev Endocrinol. 2024. PMID: 39138377 Review.
-
LT4/LT3 Combination Therapy vs. Monotherapy with LT4 for Persistent Symptoms of Hypothyroidism: A Systematic Review.Int J Mol Sci. 2024 Aug 25;25(17):9218. doi: 10.3390/ijms25179218. Int J Mol Sci. 2024. PMID: 39273168 Free PMC article.
-
Implementation of thyroid-related patient-reported outcomes in routine clinical practice.Front Endocrinol (Lausanne). 2022 Sep 28;13:1000682. doi: 10.3389/fendo.2022.1000682. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36246917 Free PMC article. Review.
-
Triiodothyronine levels in athyreotic pediatric patients during levothyroxine therapy.Front Endocrinol (Lausanne). 2024 Aug 14;15:1443394. doi: 10.3389/fendo.2024.1443394. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39205688 Free PMC article.
References
-
- Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, Cooper DS, Kim BW, Peeters RP, Rosenthal MS, Sawka AM; American Thyroid Association Task Force on Thyroid Hormone Replacement 2014. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid 24:1670–1751 - PMC - PubMed
-
- Gil-Ibanez P, Belinchon MM, Morte B, Obregon MJ, Bernal J. 2017. Is the intrinsic genomic activity of thyroxine relevant in vivo? Effects on gene expression in primary cerebrocortical and neuroblastoma cells. Thyroid 27:1092–1098 - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical